MedTrace Logo

AMHR2 Polymorphism in Blood and Granulosa Cells in Unexplained Infertility

NCT05592730 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2023-05-06

No results posted yet for this study

Summary

There are various known parameters for assessing ovarian reserve, including ovarian volume, antral follicle count, follicle stimulating hormone (FSH) and Inhibin B at the beginning of the menstrual cycle, as well as anti-Mullerian hormone (AMH). Anti-müllerian hormone is a dimeric glycoprotein and a member of the transforming growth factor β family that plays a role in the regulation of follicular development. AMH is produced by granulosa cells of the early developing follicles in the ovary, and continues to be expressed in the growing follicles until these follicles have reached a size of 4-6 mm and a differentiation state at which AMH becomes receptive for exogenous FSH, and may be selected for dominance.It exerts its biological effects through the receptor AMHR2, which is present on granulosa and theca cells. Considering the important role of the AMH signalling pathway in regulating FSH sensitivity in the ovary and follicular recruitment and selection, it is appropriate to consider that variation in the genes encoding key proteins in the pathway may influence ovarian response. The aim of this study is to investigate the effect of the distribution of single gene polymorphisms of the AMHR2 receptor gene A-482G/rs200255 in patients with unexplained infertility and to compare this distribution with the distribution in women without infertility.

Conditions

  • Infertility, Female
  • AMH
  • IVF

Interventions

GENETIC

AMHR2 polymorphism in blood

1 tube of blood taken at the first application

GENETIC

AMHR2 polymorphism in granulosa cell

Extraction of granulosa cell from the follicle fluid obtained during OPU

Sponsors & Collaborators

  • Bezmialem Vakif University

    lead OTHER

Principal Investigators

  • Pinar Ozcan, MD, PhD · BEZMİALEM VAKIF ÜNİVERSİTESİ

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05592730 on ClinicalTrials.gov